FOLH1 and prostate cancer: Further to these, in the LUNAR study (NCT05496959), patients with oligorecurrent prostate cancer (1–5 extraprostatic lesions on diagnostic PSMA PET) will be randomized between SBRT to all lesions compared to SBRT to all lesions plus two treatments of Lu-177 PSMA RLT, administered 112 days and 56 days prior to the start of SBRT.